Shanghai Junshi Bioscience Co., Ltd.

This study is testing whether combining a new drug called JS212 with other cancer medications can help control advanced lung cancer. Researchers will enroll about 864 patients whose cancer has progressed despite standard treatments or who haven't yet received systemic therapy. Th…

This study aims to test the safety and early effectiveness of a new combination therapy called JS212 for adults with advanced esophageal cancer that has spread or returned. It will involve about 280 patients who have not received prior drug treatment for their advanced disease. T…

This study is testing two new drugs, JS212 and JS213, both alone and in combination with each other and other cancer therapies, in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to see if these treatments can shrink tumors …